BridgeMD
New treatment option for Brain Metastases, Adult
Official title a Feasibility Study of iHD-SRT for BM
ClinicalTrials.gov ID: NCT06231186
What this study is testing
- What it's testing
- Brain metastasis is the most challenging disease in the field of tumor treatment, with a median overall survival of only 1-2 months for untreated patients. Stereotactic radiotherapy (SRT) has the advantages of precise positioning, relatively concentrated dosage, shorter course, and lower toxicity.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- Ability to understand and willingness to participate the research and sign the consent form
- ECOG PS 0-2
- The primary or metastatic lesion was confirmed by pathological histology as a malignant tumor
- Head MRI diagnosis of brain metastasis with measurable lesions and technically feasible SRT (no more than 15 in number and 20cc in volume)
- Estimated survival time ≥ 3 months
You likely can't join if
- Diffuse brain metastases, or combined with meningeal metastases, or technically difficult to perform SRT
- With severe internal medicine complications or absolute contraindications for radiotherapy
- other sufficient reasons to be unqualified, such as potential non-compliance with the clinical protocol, etc
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.